SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis
Yunfeng Shen, Lidan Cheng, Minxuan Xu, Wei Wang, Zhiping Wan, Haixia Xiong, Wanrong Guo, Mengyin Cai, Fen Xu
Topics & Concepts
EmpagliflozinHepatic stellate cellDownregulation and upregulationFatty liverCancer researchFibrosisHepatic fibrosisLipotoxicityMedicineThioacetamideAlcoholic liver diseaseInternal medicineEndocrinologyChemistryCirrhosisType 2 diabetesDiabetes mellitusDiseaseBiochemistryInsulin resistanceGeneLiver physiology and pathologyLiver Disease Diagnosis and TreatmentLiver Diseases and Immunity